CTRI/2023/05/052720尚未招募4 期
A Prospective, Multi-centre, Single-arm, Phase IV Study to Assess the Safety and Efficacy of Fixed Dose Combination of Brinzolamide and Timolol Ophthalmic Suspension to Decrease Intraocular Pressure (IOP) in Adult Patients with Open-angle Glaucoma or Ocular Hypertension for whom Monotherapy Provides Insufficient IOP Reduction
Sun Pharma Laboratories Limited (SPLL)0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Patients of either gender aged >= 18 years who are willing to provide written informed consent
- •2.Patients diagnosed with Primary Openâ??angle glaucoma or Ocular hypertension
- •3.Patients who are on mono-therapy of either carbonic anhydrase inhibitors (CAIs) or Beta-blockers or any other IOP-lowering therapy and not adequately controlled
- •4.Women of childbearing potential must have a negative urine pregnancy test before study entry and agree to use highly effective methods of contraception to prevent pregnancy from study entry till at least two weeks after the last dose of the study medication
- •5.Male patients must have had a successful vasectomy or they and their female partners must meet the criteria above
排除标准
- •1.Patients with a history of allergic hypersensitivity to oral or topical Carbonic Anhydrase Inhibitors, Beta -blockers, sulfonamide drugs, or any components of these medications
- •2.Patients with acute or chronic conjunctivitis
- •3.Patients with reactive airway disease including bronchial asthma or a history of bronchial asthma, or severe chronic obstructive pulmonary disease
- •4.Patients with known/history of sinus bradycardia, sick sinus syndrome, sino-atrial block, second or third degree atrioventricular block not controlled with pace-maker, overt cardiac failure, and cardiogenic shock
- •5.Patients with uncontrolled hypertension, dry eye syndrome, diabetic retinopathy, hyperchloraemic acidosis and uncontrolled diabetes
- •6.Patients with severe allergic rhinitis
- •7.Patients using intraocular corticosteroid implant
- •8.Patients using contact lenses within 1 week prior to enrolment
- •9.Patients using the following medications within two weeks prior to baseline of: 1) topical ophthalmic corticosteroid; 2) topical corticosteroid; 3) systemic corticosteroid, or 4) high dose salicylate therapy
- •10.Patients using intravitreal or subtenon injection of ophthalmic corticosteroid within 6 months prior to enrolment
- •11.Patients who are anticipated the need to initiate or modify medication that is known to affect IOP during the study period
- •12.Patients with severe renal impairment
- •13.Patients undergone intraocular surgery or laser surgery within the past 3 months
- •14.Patients currently using any systemic corticosteroid, or is having had therapy with any investigational agent within past 30 days
- •15.Patients with history of hematologic disorders other than mild anemia
- •16.Patients with history of non-compliance to medical regimens or those patients unwilling to comply with the study protocol
- •17.Patients with history of or currently having any of the severe/serious ocular condition or clinically significant medical conditions, such as cardiovascular, respiratory, renal, hepatic, endocrine, or gastrointestinal disease
- •18.Patients with history of or known case of HIV-AIDS, hepatitis B (Hep B), and hepatitis C (Hep C)
- •19.Participation in other studies involving investigational drugs or surgeries within the last 30 days or investigational biologics within the last 6 months prior to screening
- •20.Pregnant or lactating women and women of childbearing potential who are not using contraceptives
- •21.Investigator, study personnel, Sponsor representatives and their first degree relatives
研究者
相似试验
已完成
4 期
Safety and Efficacy of Amantadine Tablets for the Treatment of Parkinsons Disease (A disorder of the central nervous system that affects movement, often including tremors) and Drug-induced Extrapyramidal Reactions (involuntary or uncontrollable movements, tremors, muscle contractions) in PatientsCTRI/2023/04/051973Sun Pharma Laboratories Limited (SPLL)163
已完成
4 期
Safety and Efficacy of Cariprazine Capsules in Adult Patients with Schizophrenia (a disorder that affects a persons ability to think, feel and behave clearly) and Acute Treatment of Manic or Mixed Episodes Associated with Bipolar I Disorder (mood swings that include emotional highs and lows)CTRI/2023/05/052793Sun Pharmaceutical Industries Limited172
尚未招募
4 期
Effects of Amoxycillin and Potassium Clavulanate Oral Syrup in Children With Respiratory InfectioCTRI/2023/08/056267Sun Pharmaceuticals Industries Limited SPI
尚未招募
4 期
A study of Fixed Dose Combination of Tamsulosin and Tadalafil Capsules to check safety and efficacy in Patients with Benign Prostatic Hyperplasia and Erectile Dysfunction.CTRI/2022/06/043152Sun Pharma Laboratory Limited SP
已完成
4 期
A clinical study to assess the efficacy and safety of Glycopyrrolate, Formoterol Fumarate and Budesonide Inhalation in patients with Chronic Obstructive Pulmonary DiseaseCTRI/2023/03/050717Zydus Healthcare Limited200